Метаболический синдром и почки: патогенетически обоснованные нефропротекция и снижение сердечно-сосудистого риска


https://doi.org/10.18705/1607-419X-2018-24-3-

Полный текст:


Аннотация

В настоящей статье рассматриваются вопросы медикаментозной нефропротекции у больных с метаболическим синдромом (МС), включая пациентов с неконтролируемой артериальной гипертензией. Обсуждаются возможности применения с этой целью фиксированной комбинации периндоприл + индапамид (Нолипрел А/Нолипрел А форте/Нолипрел А Би-форте «Лаборатория Сервье», Франция). На основании данных доказательной медицины четко обозначены преимущества данной комбинации: благоприятное влияние на адипокины, уровень неинфекционного воспаления, эластичность крупных сосудов, что делает ее единственной эффективной на всех этапах ренального континуума у пациентов с МС и ХБП и подтверждается положительным влиянием на риск развития сердечно-сосудистых и почечных осложнений.


Об авторе

С. В. Недогода
Волгоградский государственный медицинский университет Минздрава России
Россия
заведующий кафедрой терапии и эндокринологии факультета усовершенствования врачей. SPIN-код: 7005-7846.


Список литературы

1. World Health Organization, Report of a WHO consultation: definition of metabolic syndrome in definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus, 1999.

2. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U. S. adults. Ann Intern Med. 2004 Feb 3;140(3):167-74.

3. Chen J, Gu D, Chen CS, Wu X, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007 Apr:22 (4):1100-6

4. Ninomiya T, Kiyohara Y, Kubo M, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. American Journal of Kidney Diseases. 2006;48(3):383- 391.

5. Kurella, M., Lo, J. C., & Chertow, G. M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. Journal of the American Society of Nephrology. 2005;16(7), 2134-2140.

6. Maggio A, Wacker J, Montecucco F, Galan K, Pelli G, Mach F, Beghetti M, Farpour-Lambert N. Serum resistin and inflammatory and endothelial activation markers in obese adolescents. J Pediatr. 2012;161:1022– 1027.

7. Maffei M, Halaas J, Ravussin E, Pratley R, Lee G, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern P, Friedman J. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995;11:1155–1161.

8. Lönnqvist F, Nordfors L, Jansson M, Thörne A, Schalling M, Arner P. Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest. 1997;99:2398–2404.

9. Meyer C, Robson D, Rackovsky N, Nadkarni V, Gerich J. Role of the kidney in human leptin metabolism. Am J Physiol Endocrinol Metab. 1997;273: E903–E907.

10. Montani J, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes. 2002;26: S28–S38.

11. Kramer H, Saranathan A, Luke A, Durazo-Arvizu R, Guichan C, Hou S, Cooper R. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol. 2006;17:1453–1459.

12. Martinez Cantarin M, Waldman S, Doria C, Frank A, Maley W, Ramirez C, Keith S, Falkner B. The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int. 2013;83:487– 494.

13. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira A, Beck G, Kusek J, Collins A, Levey A, Sarnak M. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2599–2606.

14. Menzaghi C, Salvemini L, Fini G, Thompson R, Mangiacotti D, Di Paola R, Morini E, Giorelli M, De Bonis C, De Cosmo S, Doria A, Trischitta V. Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. PLoS One. 2012;7:e38414.

15. Agrawal S, Shlipak MG, Kramer H, Jain A, Herrington DM. The association of chronic kidney disease and metabolic syndrome with incident cardiovascular events: multiethnic study of atherosclerosis. Cardiol Res Pract. 2012;2012:806102. doi: 10.1155/2012/806102.

16. Kunimura A, Amano T, Uetani T, et al. Prognostic impact of concurrence of metabolic syndrome and chronic kidney disease in patients undergoing coronary intervention: involvement of coronary plaque composition. J Cardiol. 2013;61(3):189–195.

17. Johnson D.W.,Armstrong K.,Campbell S.B.,et al. Metabolic syndrome in severe chronic kidney disease: prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton). 2007;12(4):391–398.

18. Kim CS, Choi JS, Bae EH, et al; Korea Acute Myocardial Infarction Registry Investigators. Association of metabolic syndrome and renal insufficiency with clinical outcome in acute myocardial infarction. Metabolism. 2013;62(5):669–676.

19. Xu H., Huang X., Arnlöv J., et al. Clinical correlates of insulin sensitivity and its association with mortality among men with CKD stages 3 and 4. Clin J Am Soc Nephrol. 2014;9(4):690–697.

20. Chan DT, Watts GF, Irish AB, Ooi EM, Dogra GK. Insulin resistance and the metabolic syndrome are associated with arterial stiffness in patients with chronic kidney disease. Am J Hypertens. 2013;26(9):1155–1161.

21. Sarafidis PA, Ruilope L.M. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. American Journal of Nephrology. 2006;26(3):232-244

22. Perlstein TS, Gerhard-Herman M, Hollenberg NK, et al. Insulin induces renal vasodilation, increases plasma renin activity, and sensitizes the renal vasculature to angiotensin receptor blockade in healthy subjects. J Am Soc Nephrol 2007;18:944-951.

23. Khamaisi M, Flyvbjerg A, Haramati Z, et al. Effect of mild hypoinsulinemia on renal hypertrophy: growth hormone/insulin- like growth factor 1 system in mild streptozotocin diabetes. Int J Exp Diab Res. 2002;3:257-264.

24. Wang S, DeNichilo M, Brubaker C, Hirschberg R. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int. 2001;60:96-105.

25. Savage DB, Sewter CP, Klenk ES, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans. Diabetes. 2001 Oct;50(10):2199-2202.

26. Jessica F. Briffa, Andrew J. McAinch, Philip Poronnik, and Deanne H. Hryciw Adipokines as a link between obesity and chronic kidney disease Am J Physiol Renal Physiol. 2013;305: F1629–F1636.

27. Jonas Axelsson and Peter Stenvinkel Role of fat mass and adipokines in chronic kidney disease Current Opinion in Nephrology and Hypertension. 2008; 17:25–31.

28. Vaia D. Raikou a Sotiris Gavriil Metabolic Syndrome and Chronic Renal Disease. Diseases 2018;6(1):12. doi:10.3390/diseases6010012.

29. Khaled Nashar1 Brent M egan2Relationship between chronic kidney disease and metabolic syndrome: current perspectives Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2014;7:421–435.

30. Dagogo-Jack S, Ovalle F, Landt M, Gearing B, Coyne D. Hyperleptinemia in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int. 1998;18:34–40.

31. Merabet E, Dagogo-Jack S, Coyne D, Klein S, Santiago J, Hmiel S, Landt M. Increased plasma leptin concentration in end-stage renal dis- ease. J Clin Endocrinol Metab. 1997;82:847–850.

32. Sharma K, Considine R, Michael B, Dunn S, Weisberg L, Kurnik B, Kurnik P, O’Connor J, Sinha M, Caro J. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int. 1997;51:1980 –1985.

33. Axelsson J, Bergsten A, Qureshi A, Heimbürger O, Bárány P, Lön- nqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int. 2006;69:596–604.

34. Menzaghi C, Salvemini L, Fini G, Thompson R, Mangiacotti D, Di Paola R, Morini E, Giorelli M, De Bonis C, De Cosmo S, Doria A, Trischitta V. Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. PLoS One. 2012;7:e38414.

35. Malyszko J, Malyszko J, Mysliwiec M. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney al- lograft recipients. Transplant Proc. 2009;41:150–153.

36. Doumatey A, Zhou J, Huang H, Adeleye J, Balogun W, Fasanmade O, Johnson T, Oli J, Okafor G, Amoah A, Eghan B, Agyenim-Boateng K, Acheampong J, Adebamowo C, Adeyemo A, Rotimi C. Circulating adiponectin is associated with renal function independent of age and serum lipids in West Africans. Int J Nephrol. 2012;2012:730920. doi: 10.1155/2012/730920.

37. Sharma K, Ramachandrarao S, Qui G, Usui H, Zhu Y, Dunn S, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B, Goldstein B. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118:1645–1656.

38. Недогода С.В. Ожирение в практике терапевта. М.: Эксмо-Пресс; 2017. 304 с.

39. London G.M., Asmar R.G., O'Rourke M.F., Safar M.E. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004;43:92–99.

40. Карпов Ю.А., Деев А.Д. от имени врачей - участников исследования ПРИВИЛЕГИЯ. Исследование ПРИВИЛЕГИЯ - Престариум В лечении артериальной гипЕртонии: антиГИпертензивнаЯ эффективность и безопасность в сравнении с эналаприлом. Кардиология 2007;7:35-40. [Karpov Iu.A., Deev A.D. Participants of the PRIVILEGIYA Study. PRIVILEGIYA (Privilige) Study — Prestarium in the treatment of arterial hypertension: antihypertensive efficacy and safety in comparison with enalapril. Kardiologiia 2007;47:35–40. In Russian].

41. Ionescu D.D. PREFER Investigators. Antihypertensive efficacy of perindopril 5–10 mg/day in primary health care: an open-label, prospective, observational study. Clin Drug Investig 2009;29(12):767–776.

42. Fennessy P.A., Campbell J.H., Mendelsohn F.A., Campbell G.R. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol 1996;23(8):S30–32.

43. Koz C., Baysan O., Yokusoglu M. et al. The effects of perindopril on aortic elasticity and inflammatory markers in hypertensive patients. Med Sci Monit 2009;15(7):PI 41–45.

44. Nedogoda S. et al. Randomized Trial of Perindopril, Enalapril, Losartan And Telmisartan in Overweight or Obese Patients With Hypertension. Clin Drug Investig 2013,33:553–561.

45. The Scientific Committee of the PERTINENT Sub-Study on behalf of the EUROPA-PERTINENT Investigators. PERTINENT-perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovasc Drugs Ther 2003;17:83–91.

46. Tropeano A., Boutouyrie P., Pannier B. et al. Brachial Pressure-Independent Reduction in Carotid Stiffness After Long-Term Angiotensin-Converting Enzyme Inhibition in Diabetic Hypertensives. Hypertension. 2006;48:80–86.

47. Недогода С.В., Смирнова В.О., Хрипаева В.Ю. и др. Возможности индапамида в ангиопротекции у пациентов с метаболическим синдромом после терапии тиазидсодержащими комбинациями. Сердце: журнал для практикующих врачей. 2016;15(3):193–197. [Nedogoda S.V., Smirnova V.O., Hripaeva V.Ju. et al. Angioprotective possibilities of indapamide in patients with metabolic syndrome after thiazide-based combinations therapy. Russian Heart Journal 2016;15(3):193–197. In Russian].

48. Недогода С.В., Ледяева А.А., Чумачек Е.В., Цома В.В., Мазина, Г.Г., Саласюк А.С., Барыкина И.Н. Сравнительная эффективность периндоприла А и лозартана у пациентов с артериальной гипертензией и ожирением. Российский кардиологический журнал. 2012;1(93):63-69. [Nedogoda S.V., Ledyaeva A.A., Chumachek E.V., Tsoma V.V., Mazina G.G., Salasyuk A.S., Barykina I.N. Comparative effectiveness of perindopril A and losartan in patients with arterial hypertension and obesity. Russian Journal of Cardiology. 2012;1(93):63-69. In Russian].

49. Недогода С.В., Чумачек Е.В., Ледяева А.А., Цома В.В., Саласюк А.С., Смирнова В.О., Хрипаева В.Ю., Палашкин Р.В. Оптимизация контроля артериального давления, органопротекции и метаболических нарушений с помощью фиксированной комбинации периндоприл и индапамида у пациентов с артериальной гипертензией. Кардиология. 2017;2:5-11. [Nedogoda S.V., Chumachek E.V., Ledyaeva A.A., Tsoma V.V., Salasyuk A.S., Smirnova V.O., Hripaeva V.Ju., Palashkin R.V.Optimization of blood pressure control, metabolic disorders and target organs protection with perindopril + indapamide fixed combination in treated hypertensive patients. Kardiologiia. 2017;2:5-11. In Russian].

50. Недогода С. В. Нефропротекция при сахарном диабете 2 типа: Уроки исследования ADVANCE. Фарматека. 2011;14:40-43. [Nedogoda S.V. Renoprotection in type 2 diabetes mellitus patients: results of the ADVANCE study. Pharmateca. 2011;14:40-43. In Russian].


Дополнительные файлы

Для цитирования: Недогода С.В. Метаболический синдром и почки: патогенетически обоснованные нефропротекция и снижение сердечно-сосудистого риска. Артериальная гипертензия. 2018;24(3). https://doi.org/10.18705/1607-419X-2018-24-3-

For citation: . . "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2018;24(3). (In Russ.) https://doi.org/10.18705/1607-419X-2018-24-3-

Просмотров: 73

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)